vs
Side-by-side financial comparison of DELUXE CORP (DLX) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
DELUXE CORP is the larger business by last-quarter revenue ($535.2M vs $339.0M, roughly 1.6× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 2.2%, a 11.0% gap on every dollar of revenue. On growth, DELUXE CORP posted the faster year-over-year revenue change (2.8% vs -2.7%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs 0.0%).
Deluxe Corporation is an American company that provides payment processing, data services, checks and promotional products, and merchant services. It operates in four divisions: B2B payments, data, print, and merchant services. As of 2025, the company serves millions of small businesses and thousands of financial institutions, processing more than $2.8 trillion in payments annually. While its legacy business centers on check printing and other printed products, payments and data services now ...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DLX vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $535.2M | $339.0M |
| Net Profit | $12.0M | $44.7M |
| Gross Margin | 52.2% | 59.7% |
| Operating Margin | 8.9% | 19.9% |
| Net Margin | 2.2% | 13.2% |
| Revenue YoY | 2.8% | -2.7% |
| Net Profit YoY | -5.0% | 19.3% |
| EPS (diluted) | $0.25 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $535.2M | $339.0M | ||
| Q3 25 | $540.2M | $327.3M | ||
| Q2 25 | $521.3M | $321.4M | ||
| Q1 25 | $536.5M | $330.6M | ||
| Q4 24 | $520.6M | $348.5M | ||
| Q3 24 | $528.4M | $345.5M | ||
| Q2 24 | $537.8M | $336.2M | ||
| Q1 24 | $535.0M | — |
| Q4 25 | $12.0M | $44.7M | ||
| Q3 25 | $33.7M | $38.7M | ||
| Q2 25 | $22.4M | $34.0M | ||
| Q1 25 | $14.0M | $58.0M | ||
| Q4 24 | $12.6M | $37.5M | ||
| Q3 24 | $8.9M | $33.8M | ||
| Q2 24 | $20.5M | $38.4M | ||
| Q1 24 | $10.8M | — |
| Q4 25 | 52.2% | 59.7% | ||
| Q3 25 | 53.9% | 59.5% | ||
| Q2 25 | 53.6% | 59.8% | ||
| Q1 25 | 52.4% | 58.4% | ||
| Q4 24 | 52.3% | 55.5% | ||
| Q3 24 | 53.3% | 54.2% | ||
| Q2 24 | 53.7% | 52.0% | ||
| Q1 24 | 53.0% | — |
| Q4 25 | 8.9% | 19.9% | ||
| Q3 25 | 14.0% | 17.9% | ||
| Q2 25 | 11.7% | 16.8% | ||
| Q1 25 | 9.0% | 21.6% | ||
| Q4 24 | 9.0% | 16.9% | ||
| Q3 24 | 7.9% | 15.0% | ||
| Q2 24 | 11.0% | 11.8% | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.2% | 13.2% | ||
| Q3 25 | 6.2% | 11.8% | ||
| Q2 25 | 4.3% | 10.6% | ||
| Q1 25 | 2.6% | 17.5% | ||
| Q4 24 | 2.4% | 10.8% | ||
| Q3 24 | 1.7% | 9.8% | ||
| Q2 24 | 3.8% | 11.4% | ||
| Q1 24 | 2.0% | — |
| Q4 25 | $0.25 | $0.95 | ||
| Q3 25 | $0.74 | $0.81 | ||
| Q2 25 | $0.50 | $0.70 | ||
| Q1 25 | $0.31 | $1.17 | ||
| Q4 24 | $0.28 | $0.74 | ||
| Q3 24 | $0.20 | $0.66 | ||
| Q2 24 | $0.46 | $0.74 | ||
| Q1 24 | $0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.9M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $680.7M | $911.5M |
| Total Assets | $2.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.9M | $363.4M | ||
| Q3 25 | $25.8M | $296.4M | ||
| Q2 25 | $26.0M | $292.9M | ||
| Q1 25 | $30.3M | $306.8M | ||
| Q4 24 | $34.4M | $320.8M | ||
| Q3 24 | $41.3M | $299.3M | ||
| Q2 24 | $23.1M | $344.4M | ||
| Q1 24 | $23.5M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $680.7M | $911.5M | ||
| Q3 25 | $664.1M | $849.2M | ||
| Q2 25 | $638.7M | $882.3M | ||
| Q1 25 | $622.5M | $820.8M | ||
| Q4 24 | $620.9M | $906.9M | ||
| Q3 24 | $612.7M | $878.9M | ||
| Q2 24 | $620.5M | $905.4M | ||
| Q1 24 | $608.4M | — |
| Q4 25 | $2.9B | $2.5B | ||
| Q3 25 | $2.6B | $2.4B | ||
| Q2 25 | $2.5B | $2.5B | ||
| Q1 25 | $2.6B | $2.5B | ||
| Q4 24 | $2.8B | $2.5B | ||
| Q3 24 | $2.6B | $2.5B | ||
| Q2 24 | $2.7B | $2.5B | ||
| Q1 24 | $2.7B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.1M | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 8.53× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $102.1M | $93.6M | ||
| Q3 25 | $67.1M | $111.3M | ||
| Q2 25 | $51.1M | $17.4M | ||
| Q1 25 | $50.3M | $116.6M | ||
| Q4 24 | $60.2M | $43.8M | ||
| Q3 24 | $67.9M | $48.8M | ||
| Q2 24 | $39.6M | $-27.4M | ||
| Q1 24 | $26.6M | — |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | $27.8M | $13.6M | ||
| Q1 25 | $24.3M | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | $46.7M | $39.4M | ||
| Q2 24 | $11.4M | $-33.1M | ||
| Q1 24 | $6.1M | — |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | 5.3% | 4.2% | ||
| Q1 25 | 4.5% | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | 8.8% | 11.4% | ||
| Q2 24 | 2.1% | -9.8% | ||
| Q1 24 | 1.1% | — |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | 4.5% | 1.2% | ||
| Q1 25 | 4.8% | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 4.0% | 2.7% | ||
| Q2 24 | 5.2% | 1.7% | ||
| Q1 24 | 3.8% | — |
| Q4 25 | 8.53× | 2.09× | ||
| Q3 25 | 1.99× | 2.88× | ||
| Q2 25 | 2.28× | 0.51× | ||
| Q1 25 | 3.59× | 2.01× | ||
| Q4 24 | 4.77× | 1.17× | ||
| Q3 24 | 7.60× | 1.44× | ||
| Q2 24 | 1.94× | -0.71× | ||
| Q1 24 | 2.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLX
| Services | $247.9M | 46% |
| B2B Payments | $76.3M | 14% |
| Datadrivenmarketingsolutions | $68.5M | 13% |
| Promotional Solutions Revenue | $60.9M | 11% |
| Treasurymanagementsolutions | $59.8M | 11% |
| Other | $17.3M | 3% |
| Other Web Based Solutions | $4.6M | 1% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
